Source: SYNBIO TECH INC.

Source

Exotic Pets Steal the Spotlight with Debut Reptilia Carnival and Live Insect Exhibition Featuring Over 50 Species

HONG KONG, June 5, 2026 /PRNewswire/ — Organized by Exhibition Group, the “Premium Pet Supplies Expo 2026” (the “Expo”) is being held from today until June 7 (Friday to Sunday) at Hall 3CDE of the Hong Kong Convention and Exhibition Centre. Upholding the principle of “Creating a Quality World for Pets,” the Expo brings together premium pet products and services from around the globe, including pet food and feed, beverages, apparel, toys, grooming and beauty care, cleaning products, health supplements, and enclosures, offering an ideal one-stop shopping and leisure destination for pet owners and animal lovers across Hong Kong. With the exotic pet–keeping population continuing to rise, this edition breaks the mold of conventional pet expos by placing exotic pets at center stage. For the first time, the Expo introduces a large-scale live insect exhibition, “Bug Squad,” and Hong Kong’s first major indoor “Reptilia Carnival,” extending the pet world beyond cats and dogs to embrace reptiles, insects, and a diverse array of species.

The opening ceremony was attended by Dr. Bernard Chan, Under Secretary for Commerce and Economic Development of the Government of the Hong Kong Special Administrative Region, Dr. Michael Chan, Honorary Chairman of Hong Kong Institute of Marketing, Ms. Angela Chan, Chairman of Hong Kong Pet Trade Association, Mr. George Lee, Vice President, Business Development, Mastercard, Ms. Julien Chen, Vice President, Marketing and Business Development, The Club, Dr. Sharon Kwok, Ambassador for Endangered Species, Mr. Kenneth Wong, Convenor of the Pet Rights Concern Unit of the Liberal Party and Mr. Carl Wong, Chairman of Exhibition Group.

Mr. Carl Wong, Chairman of Exhibition Group, said, “Pets have become an indispensable part of Hong Kong families. With the Food Business (Amendment) Regulation 2026 coming into effect and travelling with pets becoming increasingly convenient, Hong Kong is steadily evolving into a pet-friendly city, while the pet economy continues to diversify. In addition to curating premium products from around the world for cat and dog owners, this year’s Expo places special focus on the rapidly growing exotic pet market. By launching the Reptilia Carnival and a large-scale live insect exhibition for the first time, we enable pet enthusiasts of all kinds to find what they need at the Expo, while also promoting life education and introducing the public to a more diverse biological world. We are also delighted to see an increasing number of well-known brands crossing over into the pet market, reflecting the industry’s confidence in the pet economy. The Expo will continue to serve as a vital platform connecting brands with consumers.”

Live Insect Exhibition “Bug Squad” Featuring Over 50 Species Makes Its Debut — Three “World-Class” Stars Become Must-Visit Photo Spots
The “Bug Squad” makes its debut at the Expo, offering visitors young and old a life education experience that goes beyond the classroom. The exhibition showcases over 50 rare insect species from around the globe, including katydids, mantises, dynastid and stag beetles, stick insects, beetles, and arthropods. Three “world-class” star specimens command the most attention: the “Giant Chinese stick insect”, the world’s longest insect species; the “Jungle nymph,” the world’s heaviest insect species; and the “Violin Beetle” (Mormolyce), a creature most people have only ever glimpsed in documentaries. This unique exhibition provides a rare opportunity for the public to observe and appreciate these extraordinary creatures up close. Through close-up observation of the live insects’ physical forms, behaviors, and ecological roles, visitors can experience the wonders of biodiversity firsthand, nurturing curiosity about and respect for different forms of life, understanding the irreplaceable value of every species within an ecosystem, and inspiring the next generation to cherish nature and treasure all living things.

Hong Kong’s First Large-Scale Indoor Reptile Carnival Launches — Immersive Beetle Pavilion “Beetle Forest” Makes a Welcome Return
Hong Kong’s first major indoor reptile activity space, the “Reptilia Carnival,” is tailor-made for reptile enthusiasts. It features a dedicated lounge and social area where owners can bring their beloved reptile companions, meet fellow hobbyists, and browse a curated reptile marketplace stocked with a full range of supplies. Complemented by immersive photo backdrops and fun reptile workshops, the Carnival provides a one-stop gathering point for the reptile community.

At the same time, the immersive “Beetle Forest” pavilion, which proved hugely popular at last year’s Expo, makes a welcome return, allowing visitors to appreciate their unique ecology. On display are numerous spectacular beetle species, including the “Hercules Beetle” (Dynastes hercules), the world’s largest insect; the king of beetles, the Rhinoceros Beetle; the colorful Rainbow Stag Beetle; the “Borneo Atlas Beetle,” one of Asia’s largest dynastid beetles; the largest Eastern Hercules Beetle (Dynastes tityus) bred in Hong Kong — a record-holder surpassing Japan — and the nationally beloved “Japanese Giant Stag Beetle” (Dorcus hopei binodulosus). Visitors can immerse themselves in the insects’ natural world, observing at their leisure and even placing beetles on their hands for photos. Admission to this activity requires a separate ticket. The first 300 ticket holders each day will receive a complimentary random beetle keychain on a first-come, first-served basis.

World Cup Fever Sweeps the Venue — “Doggy Games” Infused with Football Fun as Furry Friends Transform into Stars
The popular “Olympets” returns with a host of entertaining competitive events, including the 50-foot sprint, Triathlon of Iron Dogs, and the weave-and-obstacle relay. To ride the wave of 2026 FIFA World Cup excitement, this year’s Games feature special football-themed elements, while a World Cup–themed photo zone invites furry companions and their owners to soak up the football frenzy together. Local pet apparel brand Momoji (Booth: 3D-F18) has also seized the moment to launch its new “MOMOJI FC” collection, drawing design inspiration from eight world-class football jerseys to create pet-exclusive scarves that transform beloved companions into pitch-side stars, ready to join their owners in celebrating the quadrennial football extravaganza.

Leading Brands Make Their Expo Debut — Cross-Industry Players Tap into the Pet Market
The immense potential of the pet economy has drawn a growing number of traditional non-pet brands into the space. This year’s Expo has attracted several prominent brands making their first appearance, extending their product development into the pet sector with new ranges designed specifically for pets and pet-owning households, and leveraging the Expo as a promotional platform to directly reach target consumers and capitalize on pet market opportunities. They include:

• Vinda Pawz (Booth: 3C-L29): Hong Kong’s No. 1 tissue brand* Vinda has launched pet pure-water wet wipes and antibacterial pee pads, certified by SGS Hong Kong dermatological testing and Germany’s Dermatest, formulated with pet-friendly ingredients to deliver a more comprehensive hygiene care experience for pet families. Free pee pad sample packs are available on-site, and customers who spend HK$100 or more can add just $1 to redeem a limited-edition Snoopy shopping bag. *Based on NielsenIQ retail audit reports for toilet tissue and soft-pack tissue across Hong Kong, July 2017 to June 2025 (© 2025 NielsenIQ)
• Dettol (Booth: 3C-P07): A plant-based Multi-Surface Antiseptic Liquid has been introduced, featuring a formula assessed by U.S. veterinarians and designed for use in homes with pets. Formulated with plant-based antibacterial ingredients, the product delivers up to 99.99% germ-killing efficacy and effectively eliminates 99.99% of common pathogens associated with cats and dogs. At the event, visitors can take part in a fun on-site pet quiz for a chance to receive complimentary laundry capsule samples. Guests who join the booth activities can also redeem exclusive pet-themed keychains, adding an extra touch of enjoyment to the experience.
• Jung Kwan Jang (Booth: 3D-H07): The world’s No. 1 ginseng brand Jung Kwan Jang is debuting in Hong Kong with its GINIPET Korean Red Ginseng dog food range, a bestseller in Korea for 10 years. Clinically validated by Seoul National University’s College of Veterinary Medicine, the formula has been proven to boost pets’ immunity by 1.9 times. Featuring a proprietary formula combined with hydrolyzed protein technology, it is hypoallergenic, easy to absorb and digest, and comes in three flavors with a crispy texture that even the fussiest eaters will love — a truly science-backed dog food for the new generation of pet owners. Free sample packs and a photo zone are available on-site.
• Choi Fung (Booth: 3E-B07): The C.F.Life pet range has launched a pet floor disinfectant cleaner that has passed SGS safety testing. Formulated with pet-friendly ingredients designed for households with pets and children, it uses specially selected natural enzymes and antibacterial agents that are gentle and non-irritating, killing 99.9% of germs and effectively removing lingering pet odors. Also available is a pet flea and tick repellent spray with potent active ingredients that combat ticks and fleas and relieve redness caused by insect bites.

Dual Spending Rewards — Swipe to Win Air Tickets Plus Points-to-Voucher Conversion
Visitors can also participate in the “Mastercard Scratch Card Lucky Draw”. During the Expo, for every $250 spent in a single transaction at designated booths with a Mastercard, visitors will receive one lucky draw chance; $500 earns two chances, and so on, up to a maximum of 10 chances per receipt. Participants can redeem scratch cards at the draw counter and instantly find out if they have won. Prizes include round-trip air tickets for two to Tokyo, Seoul, or Taipei, supermarket vouchers, and more. (Licence Numbers: 061395, 061397; terms and conditions apply.)

Exhibition Group also continues its partnership with The Club, under HKT, to run the “Point2Purchase Consumption Vouchers” programme. Since its launch last year, the programme has been piloted at multiple exhibitions to positive response. Over 4 million members of The Club can convert accumulated points into Expo-exclusive spending vouchers via the app, redeem physical vouchers at the dedicated counter in the venue, and use them instantly at designated booths — further encouraging local spending and delivering a win-win for both exhibitors and consumers.

Premium Pet Supplies Expo 2026

About Exhibition Group
Exhibition Group Limited is one of Hong Kong’s renowned exhibition companies. Our core team has been assembled since 2003, bringing together a group of innovative, experienced, and professional exhibition talents. As a leading event management company, specializing in the planning and operation of world-class public exhibitions, conferences, and trade fairs, covering a wide range of industries. With years of industry experience, we are committed to the development of exhibition and marketing businesses, gaining a prestigious reputation within the exhibition industry.

Our company organizes a variety of themed exhibitions and marketing projects, which not only receive substantial support from the business community and exhibitors but also effectively attract a large number of public participants. Each event has garnered rave reviews, resulting in a win-win situation for exhibitors in both product promotion and sales. Notable exhibitions include the Pet Show, In-Home Expo, Premium Pet Supplies Expo, Hong Kong Cat Expo, Hong Kong Holiday & Travel Expo, Extracurricular Activities Festival cum Teaching Materials and Supplies Expo, and Hong Kong Outdoor & Sports Expo, among others. In recent years, our company has been honored with several awards, including the “Outstanding Award for Pandemic Resilience,” “ESG Commendation Awards,” and “Innovative Exhibition Planning,” recognizing our business development achievements across various sectors.

This press release is distributed by Market Hubs Holdings Limited.

Source

ST. PETERSBURG, Russia, June 5, 2026 /PRNewswire/ — The Russian edition of the first volume of “China’s Governance Under Xi Jinping’s Leadership” was launched at the 29th St. Petersburg International Economic Forum on Wednesday.

Roughly over 100 representatives from media outlets, think tanks and government authorities of China, Russia and other countries attended the launch ceremony.

During the ceremony, President of Xinhua News Agency Fu Hua, TASS Director General Andrey Kondrashov and Chinese Consul General in St. Petersburg Luo Zhanhui jointly unveiled the new book.

Participants of the event noted that the book is a documentary work presenting a panoramic view of the great practices and remarkable achievements in China’s governance in the new era. Packed with detailed case studies, objective perspectives and systematic elaboration, it fully documents China’s arduous journey of overcoming difficulties and forging ahead in the new era.

The Russian edition of the book is expected to serve as an authoritative and vivid reference for people from various walks of life in Russia seeking to better understand how China has achieved its development and the effectiveness of its governance, while also building a solid bridge for deeper China-Russia cultural exchanges, said the participants.

Compiled by Xinhua News Agency and published by Xinhua Publishing House for global distribution, the first volume of “China’s Governance Under Xi Jinping’s Leadership” is now available in Chinese, English, Arabic, Russian and other languages. 

Source

• The line-up includes two new para-athletes – Indonesian para cyclist Muhammad Fadli Imamuddin and Malaysian para-athletics sprinter Muhammad Ammar Aiman Nor Azmi – alongside five returning athletes from the Paris 2024 cycle.
• Each athlete will be paired with a Dual Hero Project, a Toyota-supported initiative within the Asia region that gives back to the communities that shaped them.

SINGAPORE, June 5, 2026 /PRNewswire/ — Toyota Motor Asia (TMA) today announced its refreshed line-up of seven Global Team Toyota Athletes (GTTAs) representing six countries across Southeast Asia, on the road to the Aichi-Nagoya 2026 Asian Games and Asian Para Games. The roster includes two new para-athletes, alongside returning athletes from the Paris 2024 cycle. This is also unified under Toyota’s regional brand platform, Move Your World, and reflects the company’s enduring belief that sport reveals what it truly means to be human.

Two new athletes join the Asia line-up

Fresh to the team are Indonesia’s Muhammad Fadli Imamuddin and Malaysia’s Muhammad Ammar Aiman Nor Azmi, who will join five Global Team Toyota Athletes from Indonesia, Malaysia, Philippines, Singapore, Thailand and the Vietnam across a range of sporting disciplines. Since 2018, Toyota has partnered with over 20 Global Team Toyota Athletes in Asia, supporting athletes who not only represent sporting excellence, but also embody the power of movement to drive progress beyond competition. As Toyota continues to evolve, its athlete partnerships remain a key expression of its Move Your World philosophy, where mobility extends beyond movement to create access, opportunity and progress within communities. Through the Global Team Toyota Athletes, Toyota continues to champion sport as a platform for inspiration, inclusion and meaningful community impact.

The full line-up of Global Team Toyota Athletes include:

“At Toyota, sport is a reflection of the human experience — the hope, the doubt, the dignity in defeat and the joy of moving forward together.

Across Asia, our seven Global Team Toyota Athletes embody that spirit, and it is our privilege to stand beside these athletes that continue to inspire and demonstrate how far dedication and courage can take them, both in competition and beyond.

Their journeys highlight the power of sport and its ability to open up new possibilities. Through Move Your World, we aim to support their ambitions in the lead-up to Aichi-Nagoya 2026, and to work alongside them in creating lasting impact in the communities that shaped them.” — Preston Tan, Vice President, Toyota Motor Asia

Dual Hero Projects: Turning Athlete Journeys into Community Impact

As part of the long-standing partnership with athletes in Asia, Toyota continues to drive positive impact through its Dual Hero Projects. Launched in 2018, the initiative pairs each athlete with a Toyota-supported project tied to a cause they care deeply about – extending their impact beyond competition and into the communities that shaped them. Since its inception, the programme has supported over 20 athlete-led initiatives across the region. 

In Singapore, Paralympic swimmer Toh Wei Soong co-created a 16-piece adaptive fashion collection that challenges perceptions of disability through inclusive design. In the Philippines, Paralympic champion Ernie Gawilan led a nationwide coastal cleanup and mangrove restoration initiative, mobilizing more than 1,300 volunteers across 33 sites and planting over 10,000 mangroves – restoring the very waters that accompanied his journey as an athlete. 

Similar Dual Hero Projects will be developed with each Asia GTTA across the span of our partnership with them.

Sport at the heart of Move Your World

As preparations for Aichi-Nagoya 2026 begin, Toyota’s expanded Asia athlete line-up brings together athletes who are not only striving for sporting excellence but also working to move their communities forward. Through sport, advocacy and local action, their journeys reflect the spirit of Move Your World – a belief that movement is most powerful when it opens doors for others.

About Toyota Motor Asia
Toyota Motor Asia is the regional corporate headquarters and subsidiary of Toyota Motor Corporation, based in both Singapore and Thailand.

Toyota Motor Asia leads and supports the Asia Pacific region in Sales and Marketing activities, Service Parts, Accessories and Customer Services, Product Planning, Production Control & Logistic, and Aftersales thus contributing to the overall development of auto industry and the growing economies in the region.

Toyota envisions the future mobility society to bring freedom of movement to all. Moving forward, Toyota will provide a diverse range of mobility services and transportation solutions to people around the world as we transform Toyota into a mobility company.

About Move Your World
Move Your World is Toyota’s regional brand platform across Asia, built on the belief that mobility is more than movement — it is what allows people to participate, to belong and to thrive. Through music, sport and community, Move Your World invites everyone in Asia to look up, to join, and to move the world forward, together.

Source

NANJING, China, June 5, 2026 /PRNewswire/ — NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally have a poor prognosis. For advanced solid tumor patients who do not receive targeted therapy, the median overall survival ranges from 10.2 to 12.7 months, and these patients are also at a higher risk of brain metastasis. Meanwhile, the loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective. Currently, treatment primarily relies on small-molecule TRK inhibitors that target the kinase domain.^1-3

In terms of tumor type distribution, NTRK fusions are characterized by rare mutations with broad tumor spectrum distribution. On one hand, the incidence of NTRK fusions reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. On the other hand, real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring close clinical attention. In addition, the prevalence of NTRK fusions is higher in East Asian populations, with an overall incidence of approximately 0.4% among Chinese patients. It is estimated that more than 15,000 new cases of NTRK fusion-positive solid tumors are diagnosed in China each year.^4-5

Breaking News: Domestic Next-Generation Tumor-Agnostic Targeted Drug Eratrectinib Approved

On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib, has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.

Efficacy Breakthrough: Eratrectinib Delivers Comprehensive Clinical Benefits

Eratrectinib is a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co.,Ltd.. In pivotal registration clinical trials for patients with NTRK fusion-positive solid tumors, this pan-tumor anticancer agent has demonstrated outstanding efficacy and safety.

Registration study results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.⁶

In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission for patients.

Furthermore, for patients with baseline brain metastases, the ORR was as high as 87.5%. For patients previously treated with TRK-TKIs, the ORR reached 47.4%, reflecting robust therapeutic efficacy across these patient groups.

New Hope for Patients with NTRK Fusion Resistance

As a next-generation TRK inhibitor independently developed in China, Eratrectinib delivers durable and deep tumor remission, with potent brain penetration and a favorable overall safety profile. Different from the linear structure of first-generation TRK inhibitors, Eratrectinib features a cyclic molecular structure. Structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors.

About Vcare PharmaTech

Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) was co-founded in 2010 by professors from China Pharmaceutical University and overseas returnee experts. As a commercial-stage innovative biopharmaceutical enterprise empowered by AI for differentiated de novo drug design, the Company is dedicated to the development of novel medicines and cutting-edge therapeutics, and has been accredited as a National Key Specialized, Refined, Differential and Innovative “Little Giant” Enterprise.

Headquartered in the Biotech and Pharmaceutical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech owns an intelligent R&D headquarters spanning 21,000 square meters. It has built a full-chain innovation system covering independent new drug R&D and industrialization, ranging from AI-powered differentiated target initiation at the early discovery stage, preclinical candidate identification, integrated collaborative pharmaceutical development to green manufacturing. Boasting a robust talent pipeline, the Company employs over 900 staff members, among whom technical professionals account for more than 84%, including over 200 master’s and doctoral degree holders. Such a highly educated, specialized and innovation-driven core R&D workforce underpins the Company’s sustained technological breakthroughs and product upgrading.

Having engaged in pharmaceutical innovation for 16 years, Vcare PharmaTech adheres to the core strategy of indigenous R&D and innovation, targeting unmet clinical needs via differentiated therapeutic approaches. Centered on addressing treatment resistance, overcoming drug resistance and improving target selectivity, the Company has established a high-quality, diversified and tiered innovative drug pipeline covering major chronic illnesses including cardiovascular and cerebrovascular diseases, inflammatory autoimmune disorders and oncology, with its novel pharmaceutical discoveries positioned for global commercialization.

The Company’s core pipeline candidates feature prominent competitive edges and promising commercial prospects. Eratrectinib (VC004), a next-generation TRK inhibitor and small-molecule targeted anti-tumor agent indicated for solid tumors driven by NTRK gene fusions, delivers tumor-agnostic therapeutic benefits across a broad spectrum of indications and has obtained marketing approval in China. Sumecigrel Capsule, a novel oral P2Y12 receptor antagonist selected four times for China’s National Major Science and Technology Projects, precisely inhibits platelet activation and aggregation to block thrombosis for the prevention and treatment of cardiovascular, cerebrovascular and arterial circulatory disorders; its pivotal confirmatory clinical trials are well underway domestically. VC005, a new-generation highly selective JAK1 inhibitor, is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with robust efficacy and safety data accelerating its clinical progression.

Backed by years of technological accumulation, the Company strives to integrate AI capabilities across the entire value chain from early R&D to manufacturing, establishing an AI-enabled premium innovative drug development system and specialized technical platforms. Its R&D platforms have been officially accredited as Nanjing Key Laboratory for AI-Assisted Drug Design and Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry; its AI-directed site-specific enzyme mutation technology has been recognized as Advanced Cleaner Production Technology by Nanjing authorities. Over the past five years, the Company has secured aggregate financing exceeding RMB 1.2 billion, earning strong recognition from the capital market.

Moving forward, abiding by its founding mission of “The better Care, The better Medicines”, Vcare PharmaTech will keep advancing AI-driven original innovation and cutting-edge pharmaceutical technologies while expanding its footprint across domestic and overseas markets. Leveraging robust R&D strengths to build a differentiated novel drug portfolio, the company commits to delivering superior therapeutic options for patients worldwide and evolving into a globally influential innovative pharmaceutical enterprise.

References:

1. Nguyen MA, et al. Pathology. 2023 Aug;55(5):596-609.
2. Jiang T, et al. Acta Pharm Sin B. 2021 Feb;11(2):355-372.
3. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.
4. O’Haire S, et al. Sci Rep. 2023 Mar 13;13(1):4116.
5. Qi C, et al. Int J Cancer. 2023 Dec 1;153(11):1916-1927.
6. Vcare Pharma. Phase II Clinical Study Data of Eratrectinib[R]

Commercial Cooperation:
Strategic Development Director: Dr. Peng, peng_yuran@vcarepharmatech.com
BD Director: Liam, xu_minghua@vcarepharmatech.com

Source

HONG KONG, June 5, 2026 /PRNewswire/ — In Q1 2026, Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC). This milestone reinforces its position as a premium, innovation-driven leader in the smart home industry.

Dreame Robot Vacuum has expanded to over 120 countries and regions, opened more than 6,500 flagship stores worldwide, and surpassed 11 million cumulative unit shipments. It holds the No.1 market share in 30 countries—including over 50% in 10—supported by a sustained annual growth rate exceeding 100% for six consecutive years.

The product portfolio features industry-leading, world-first technologies, enabling devices to clean lower, reach deeper, climb higher, and operate more intelligently in real home environments. Each innovation addresses real household cleaning challenges, translating advanced technology into practical everyday value.

“Achieving No.1 globally in both sales and revenue in Q1 2026, according to IDC, marks a significant milestone for Dreame Robot Vacuum,” said Michael MENG, President of Dreame Robot Vacuum. “It reflects our long-term commitment to innovation, quality, and user-centric design. We will continue pushing the boundaries of home robotics to create smarter and more meaningful living experiences for users around the world.”

Looking ahead, Dreame Robot Vacuum will continue expanding its presence in the smart home industry, moving beyond floor cleaning toward the next generation of intelligent robotic automation.

About Dreame Technology
Established in 2017, Dreame Technology is an innovative consumer product company that focuses on smart home cleaning appliances with the vision to empower lives through technology. For more information, visit https://global.dreametech.com.

Source